Sagimet Biosciences Announces Clearance of IND for FASN Inhibitor TVB-3567, to be Developed for the Treatment of Acne
TVB-3567 is the Company’s second fatty acid synthase (FASN) inhibitorFirst-in-human Phase 1 trial initiation planned in 2025SAN MATEO, Calif., ...
Nasdaq8d
Sagimet Biosciences Announces IND Clearance for TVB-3567, a Second FASN Inhibitor Targeting Acne, with Phase 1 Trial Planned for 2025
Based on both its mechanism of action and strong preclinical profile, we believe TVB-3567 has the potential to offer a differentiated treatment option for acne. We look forward to initiating ...
Sagimet Biosciences announces clearance of IND for FASN inhibitor TVB-3567
Sagimet Biosciences (SGMT) announced the clearance of its Investigational New Drug, IND, application for TVB-3567, the Company’s second fatty ...